15.4 C
New York
Wednesday, April 24, 2024

Bank of America Upgrades Cepheid To Buy

Courtesy of Benzinga.

Related CPHD
UPDATE: Citigroup Reiterates On Cepheid Following Positive Data
Cepheid Receives FDA Clearance For Xpert Norovirus, The First On-Demand Molecular Test For Detection of Norovirus

Analysts at Bank of America upgraded Cepheid (NASDAQ: CPHD) from Neutral to Buy.

The price target for Cepheid has been raised from $56 to $60.

Cepheid shares have jumped 6.69% over the past 52 weeks, while the S&P 500 index has gained 11.23% in the same period.

Cepheid’s shares rose 4.71% to close at $49.79 yesterday.

Latest Ratings for CPHD

Date Firm Action From To
Dec 2014 Bank of America Upgrades Neutral Buy
Dec 2014 Citigroup Maintains Buy
Dec 2014 Oppenheimer Maintains Outperform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Bank of AmericaUpgrades Analyst Ratings

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,326FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x